Audentes Therapeutics (BOLD) Misses Q3 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. SPY
4. META
5. JBLU
6. ANT
7. SSD
8. ARTV
9. AAPL
10. INTC

Go back to Audentes Therapeutics (BOLD) Misses Q3 EPS by 9c

Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

November 6, 2018 4:01 PM EST

SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the third quarter ended September 30, 2018 and provided an update on the company's recent achievements and upcoming milestones.

"In the third quarter, we continued to see exciting progress in the clinical development of AT132," stated Matthew R. Patterson, Chairman and Chief Executive Officer.  "We recently presented new ASPIRO data at the 23rd International Annual Congress of the... More